AbbVie’s Dividend Has Risen 140% since 2013



Dividend overview

AbbVie (ABBV) announced its fourth-quarter dividend yield of 4.09%. On September 7, AbbVie announced a dividend of $0.96 per share to its shareholders of record on October 15.

AbbVie’s dividend has increased by 140.0% since 2013, witnessing consistent growth over the past three years. AbbVie’s dividend reached $0.96 in the second quarter, the third quarter, and the fourth quarter. AbbVie’s dividend grew from $0.57 per share during the fourth quarter of 2015 to $0.71 per share in the first quarter and finally to $0.96 per share in the fourth quarter.

Wall Street analysts expect AbbVie to deliver a dividend of $0.79 in January 2019. Analysts expect AbbVie to increase its dividend to $1.01 in the second quarter of 2019.

Article continues below advertisement

Recent developments

In September, the Committee for Medicinal Products for Human Use (or CHMP) of the European Medicines Agency (or EMA) recommended a positive opinion for AbbVie’s Venclyxto and rituximab combination therapy. This combination therapy is for the treatment of individuals with R/R CLL (relapsed or refractory chronic lymphocytic leukemia) who underwent at least one prior therapy. 

The CHMP recommended a positive opinion for Venclyxto and rituximab combination therapy based on the data from the Phase 3 MURANO trial. In this trial, the Venclyxto and rituximab combination therapy demonstrated statistically significant progress in investigator-examined PFS (progression-free survival) compared to rituximab and bendamustine combination therapy.

Financials in a nutshell

In the first half, AbbVie (ABBV) reported revenues of $16.2 billion compared to $13.5 billion in the first half of 2017, reflecting ~20% YoY (year-over-year) growth. AbbVie’s Humira and Imbruvica pushed this revenue growth. 

AbbVie’s HCV segment also significantly pushed the company’s revenue growth, reporting revenues of $1.9 billion in the first half of the year. AbbVie generated revenues of $9.9 billion and $1.6 billion from the sales of Humira and Imbruvica, respectively, reflecting ~12.0% and ~36.9% YoY growth.

In the first half, AbbVie reported net income and diluted EPS of $4.8 billion and $2.99, respectively, compared to $3.6 billion and $2.25 in the first half of 2017. The iShares US Healthcare ETF (IYH) holds AbbVie (ABBV) with ~3.67% weight in its portfolio.

Analysts’ recommendations

Of the 21 analysts tracking AbbVie stock in September, four recommended a “strong buy” while five analysts recommended a “buy” rating. Ten analysts recommended a “hold” while two analysts recommended a “sell” for AbbVie in September.

On September 26, AbbVie had consensus 12-month target price of $109.42, which represents an ~15.89% return on investment over the next 12 months.


More From Market Realist